Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07181213

Genetic Predisposition to High Blood Pressure

Primary aldosteronism (PA) is a known but underdiagnosed cause of high blood pressure. It is estimated that more than 10% of all people with high blood pressure (HT) suffer from PA, which is often caused by aldosterone-producing adrenal cortical tumors (APAs).

In a pilot study with 35 patients with APAs leading to hypertension, the investigators have identified a genetic variant in a presumed Calcium-channel gene. The variant was significantly overrepresented in patients with APAs compared to the normal population (12% compared to approximately 4%). Interestingly, all patients having APAs and the variant were men.

The SCAPIS study is a world-unique Swedish research study in the field of heart/lungs, in which 30,000 randomly selected people between the ages of 50-64 participated. The study is a collaboration between the universities of Gothenburg, Lund, Linköping, Uppsala and Umeå, as well as the Karolinska Institute in Stockholm. In Linköping, about 5,000 persons participated.

The investigators have now screened 4762 persons from the SCAPIS study for this variant and found it in little less than 6%. Overall, patients with the variant had more often been diagnosed with HT and were mote often treated for HT as well. Interestingly, this difference was only found in men.

The investigators now want to investigate the following:

1. identify those persons with the genetic variant and HT that have PA, 2. identify those persons with PA that have APAs/unilateral disease, 3. identify how many patients with APAs/unilateral disease can be cured by surgery.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Linköping University Hospital

Linköping, Östergötland County, 58185, Sweden

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients that participated in the SCAPIS study
  • patients that have a particular genetic variant
  • patients that have hypertension

Exclusion criteria

  • patients who do not want to participate
  • patients who cannot give consent
  • patients who are too sick to be operated

Treatment and study plan

Adrenalectomy

Procedure

Surgical removal of patients with unilateral primary aldosteronism in patients selected by the presence of a genetic variant and hypertension

Primary outcomes

  1. Normal aldosterone-renin-ratio

    Time frame: 6 months following surgery

Secondary outcomes

  1. Blood pressure both systolic and diastolic

    Time frame: 6 months after surgery

  2. Number of antihypertensive drugs

    Time frame: 6 months following surgery

  3. Normal potassium level

    Time frame: 6 months postoperatively

Sponsors and collaborators

Lead sponsor

Linkoeping University

Other Gov

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Sep 18, 2025
Registry last updated
Feb 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.